SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-ht1a receptor. Eur. J. Pharmacol. 2002; 441: 137140.
  • 2
    Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 2002; 302: 381389.
  • 3
    Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 28 (Suppl. 1): 926.
  • 4
    Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J. Clin. Psychiatry 2001; 62 (Suppl. 7): 3237.
  • 5
    Casey DE. Dyslipidemia and atypical antipsychotic drugs. J. Clin. Psychiatry 2004; 65 (Suppl. 18): 2735.
  • 6
    Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J. Clin. Psychiatry 2004; 65 (Suppl. 18): 3646.
  • 7
    Kikuchi T, Tottori K, Uwahodo Y et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 1995; 274: 329336.
  • 8
    Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 2002; 63: 763771.
  • 9
    Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003; 60: 681690.
  • 10
    Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 2003; 6: 325337.
  • 11
    Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. J. Clin. Psychiatry 2003; 64: 10481056.
  • 12
    Chan HY, Lin WW, Lin SK et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J. Clin. Psychiatry 2007; 68: 2936.
  • 13
    American Psychiatric Association. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association, Washington, DC, 1994.
  • 14
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261276.
  • 15
    Guy W, United States National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, George Washington University, Biometric Laboratory. ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service (ADM), Rockville, MD, 1976.
  • 16
    Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta. Psychiatr. Scand. Suppl. 1970; 212: 1119.
  • 17
    Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989; 154: 672676.
  • 18
    Keck PE Jr, McElroy SM, Strakowski SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J. Clin. Psychiatry 2000; 61 (Suppl. 3): 49.
  • 19
    Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J. Clin. Psychiatry 2006; 67: 675676.
  • 20
    Casey DE. Barriers to progress: The impact of tolerability problems. Int. Clin. Psychopharmacol. 2001; 16 (Suppl. 1): S1519.
  • 21
    Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J. Clin. Psychiatry 2001; 62 (Suppl. 7): 2231.
  • 22
    Sussman N. Review of atypical antipsychotics and weight gain. J. Clin. Psychiatry 2001; 62 (Suppl. 23): 512.
  • 23
    Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr. Res. 1999; 35 (Suppl): S75S86.